Amir Khan

US Patent:

7250405, Jul 31, 2007

Filed:

Feb 6, 2003

Appl. No.:

10/359919

Inventors:

Ruxandra Draghia-Akli - Houston TX, US
Amir Khan - Houston TX, US

Assignee:

Baylor College of Medicine - Houston TX

International Classification:

A61K 31/70
C12N 5/00
C12N 15/00
C12N 15/63
C12P 21/06
A01N 63/00
A61K 48/00

US Classification:

514 44, 435 691, 4353201, 435325, 435455, 424 931, 424 932

Abstract:

The intramuscular electroporated injection of a protease-resistant growth hormone-releasing hormone (“GHRH”) cDNA into rat dams at 16 days of gestation resulted in the enhanced long-term growth of the F1 offspring. The offspring were significantly heavier by one week of age and the difference was sustained to 10 weeks of age. Consistent with their augmented growth, plasma IGF-I concentration of the F1 progeny was increased significantly. The pituitary gland of the offspring was significantly heavier, and contained an increased number of somatotropes (cells producing GH) and lactotrophs (prolactin-secreting cells), and is indicative of an alteration in cell lineages. These unique findings demonstrate that enhanced GHRH expression in pregnant dams can result in intergenerational growth promotion, by altering development of the pituitary gland in the offspring.

US Patent:

8058253, Nov 15, 2011

Filed:

Jul 5, 2007

Appl. No.:

12/307733

Inventors:

Ruxandra Draghia-Akli - Houston TX, US
Amir S. Khan - Houston TX, US

Assignee:

VGX Pharmaceuticals, Inc. - Blue Bell PA

International Classification:

A61K 48/00
C12P 21/06
C12N 15/09
C12N 15/00
C12N 5/00

US Classification:

514 44R, 424 931, 424 932, 435 691, 435 694, 4353201, 435325, 435455

Abstract:

This invention is related to compositions and methods for decreasing cholesterol levels in a subject. The method utilizes a nucleic acid expression construct that encodes a growth-hormone-releasing-hormone (“GHRH”) that is delivered into a tissue of the subject, wherein, GHRH is expressed in vivo in the subject.

US Patent:

8209006, Jun 26, 2012

Filed:

Sep 8, 2003

Appl. No.:

10/657725

Inventors:

Louis C. Smith - Houston TX, US
Ruxandra Draghia-Akli - Houston TX, US
Amir S. Khan - Houston TX, US
Robert H. Carpenter - Bastrop TX, US
Jeff Darnell - The Woodlands TX, US

Assignee:

VGX Pharmaceuticals, Inc. - Blue Bell PA

International Classification:

A61N 1/30

US Classification:

604 21, 604 20

Abstract:

An electroporation device which may be used to effectively facilitate the introduction of a macromolecule into cells of a selected tissue in a body or plant. The electroporation device comprises an electro-kinetic device (“EKD”) whose operation is specified by software or firmware. The EKD produces a series of programmable constant-current pulse patterns between electrodes in an array based on user control and input of the pulse parameters and allows the storage and acquisition of current waveform data. The electroporation device also comprises a replaceable electrode disk having an array of needle electrodes, a central injection channel for an injection needle, and a removable guide disk.

US Patent:

20060025368, Feb 2, 2006

Filed:

Jul 21, 2005

Appl. No.:

11/186282

Inventors:

Ruxandra Draghia-Akli - Houston TX, US
Patricia Brown - Conroe TX, US
Amir Khan - Houston TX, US
William Davis - Pullman WA, US

Assignee:

ADViSYS, Inc. - The Woodlands TX

International Classification:

A61K 48/00
C12N 15/87

US Classification:

514044000, 435459000, 514002000

Abstract:

This invention discloses compositions and methods of: vaccinating a subject; enhancing the vaccination efficiency; preparing a subject prior to vaccination response; and improving the clinical outcome after infectious challenge in a subject that has been vaccinated. More specifically, the invention pertains to delivering into a tissue of the subject a nucleic acid expression construct that encodes a growth-hormone-releasing-hormone (“GHRH”) before or concomitantly with delivering a vaccine to the subject, wherein, GHRH is expressed in vivo in the subject, wherein the subject comprises a human, pig, cow, bird, horse or any other animal species receiving a vaccine.

US Patent:

20080091135, Apr 17, 2008

Filed:

Oct 17, 2007

Appl. No.:

11/874072

Inventors:

Ruxandra Draghia-Akli - Houston TX, US
Amir Khan - The Woodlands TX, US

International Classification:

A61N 1/30

US Classification:

604020000

Abstract:

Aspects of the present invention relate to electroporation devices and methods of using same to effectively facilitate the introduction of a biomolecule into cells of a selected tissue in a body, in particular skin such as intradermic or subcutaneous tissue. In some aspects, the present invention is a skin EP device, which produces a pulse of energy and delivers same to the skin tissue using a skin electrode array and maintains a constant current in the same skin tissue based on user input, including a preset current, and allows the storage and acquisition of current waveform data.

US Patent:

20080207543, Aug 28, 2008

Filed:

Jul 9, 2007

Appl. No.:

11/774954

Inventors:

Ruxandra Draghia-Akli - Houston TX, US
Amir Khan - The Woodlands TX, US

Assignee:

Baylor College of Medicine - Houston TX

International Classification:

A61K 31/7052
C12N 15/87
A61P 5/06

US Classification:

514 44, 435455, 435461

Abstract:

The intramuscular electroporated injection of a protease-resistant growth hormone-releasing hormone (“GHRH”) cDNA into rat dams at 16 days of gestation resulted in the enhanced long-term growth of the FI offspring. The offspring were significantly heavier by one week of age and the difference was sustained to 10 weeks of age. Consistent with their augmented growth, plasma IGF-I concentration of the FI progeny was increased significantly. The pituitary gland of the offspring was significantly heavier, and contained an increased number of somatotropes (cells producing GH) and lactotrophs (prolactin-secreting cells), and is indicative of an alteration in cell lineages. These unique findings demonstrate that enhanced GHRH expression in pregnant dams can result in intergenerational growth promotion, by altering development of the pituitary gland in the offspring.

US Patent:

20090156787, Jun 18, 2009

Filed:

Nov 14, 2008

Appl. No.:

12/271603

Inventors:

Ruxandra Draghia-Akli - Houston TX, US
Amir S. Khan - Houston TX, US

Assignee:

VGX PHARMACEUTICALS, INC. - Blue Bell PA

International Classification:

C07K 16/18
A61K 39/395
C07K 16/08

US Classification:

5303871, 4241381, 4241591

Abstract:

There are provided methods of generating antibodies in a mammal against recombinant antigens using DNA plasmids capable of expressing said antigens in cells of said mammal, comprising: injecting into tissue of said mammal a DNA plasmid comprising an encoding sequence operably linked to a promoter, electroporating said tissue with an electroporation device capable of delivering an electrical pulse effective to electroporate cells of said tissue to allow entry of said DNA plasmid and expression of said antigen, and allowing said mammal to respond to said expressed antigen in order to generate antibodies to said antigen. Furthermore, there are provided methods of isolating antibodies specific against desired antigens wherein said antibodies are generated in a mammal using DNA plasmids capable of expressing said antigens.

US Patent:

20180257330, Sep 13, 2018

Filed:

May 15, 2018

Appl. No.:

15/979745

Inventors:

- Tampa FL, US
Robert Hyer - Torrance CA, US
Amir G. Khan - Valrico FL, US
Andrew Troxell - Tampa FL, US

Assignee:

Gardner-Gibson, Inc. - Tampa FL

International Classification:

B32B 5/02
E04D 5/02
B32B 37/14
B32B 27/06
B32B 7/12

Abstract:

An underlayment material has a fiber mat partially infused and/or coated with asphalt and coated with silicone coating. A selvedge edge, may be coated or uncoated. The back of the underlayment has a self-adhesive coating, which is protected before use by a siliconized release film. The upper surface of the underlayment is coated with silicone composition providing waterproofing and radiation control. When unsaturated, the selvedge edge of fibrous material establishes a reinforced bond with an overlying sheet. When saturated with asphalt, the bond at the selvedge edge between adjacent sheets is between the asphalt layer of the selvedge edge and the adhesive on the bottom of the adjacent sheet.